In 2020, the Australian Government entered into four Advance Purchase Agreements (APA) for the supply of COVID-19 vaccines, if they prove safe and effective. More than $3.3 billion has been invested through these agreements, putting Australia in a strong position to access safe and effective vaccines when they become available. In 2021, three of these vaccines are still active, with the 4日 (University of Queensland) withdrawn from clinical trials. Our new reference pages detail information regarding the clinical trials of each vaccine candidate, interim data on their safety and efficacy, as well as other vaccine specific information.
To read more please refer to the links below: